Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 561-569 , July 2008

[11C]-MeJDTic: a novel radioligand for κ-opioid receptor positron emission tomography imaging

Received 26 November 2007 ,Revised 12 February 2008 ,Accepted 16 February 2008.

References 

  1. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Porthoghese PS, et al. International Union of Pharmacology: XII. Classification of opioid receptors. Pharmacol Rev. 1996;48:567–592
  2. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953–990
  3. Minami M, Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res. 1995;23:121–145
  4. Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 Years of opioid research: the exciting but vain quest for the Holy Grail. British J Pharmacol. 2006;147:S153–S162
  5. Szmuszkovicz J. U-50,488 and the kappa receptor. Part ii. Prog Drug Res. 1999;53:1–51
  6. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, et al. Disruption of the k-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective k-agonist U-50,488H and attenuates morphine withdrawal. EMBO Journal. 1998;17:886–897
  7. Narita M, Funada M, Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther. 2001;89:1–15
  8. Gottlieb HB, Varner KJ, Kenigs VA, Cabral AM, Kapusta DR. Differential cardiovascular and renal responses produced by microinjection of the k-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus. J Pharmacol Exp Ther. 2005;312:678–685
  9. Chen TY, Goyagi T, Toung TJK, Kirsch JR, Hurn PD, Koehler RC, et al. Prolonged opportunity for ischemic neuroprotection with selective k-opioid receptor agonist in rats. Stroke. 2004;35:1180–1185
  10. Manocha A, Mediratta PK, Sharma KK. Studies on the anticonvulsant effect of U50488H on maximal electroshock seizure in mice. Pharmacol Biochem Behav. 2003;76:111–117
  11. Prinsinzano TE, Tidgewell K, Harding WW. k Opioids as potential treatments for stimulant dependence. AAPS J. 2005;7:E592–E599
  12. Boutin H, Catherine A, MacKenzie ET, Jauzac P, Dauphin F. Long-term alterations in m, d and k opioidergic receptors following middle cerebral artery occlusion in mice. Acta Neuropathol. 2007;114:491–500
  13. Sheffler DJ, Roth BL. Salvinorin A: the ‘magic mint’ hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci. 2003;24:107–109
  14. Chappell PB, Leckman JF, Scahill LD, Hardin MT, Anderson G, Cohen DJ. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. 1993;47:267–280
  15. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res. 2001;893:121–134
  16. Machulla HJ, Heinz A. Radioligands for brain imaging of the k-opioid system. J Nucl Med. 2005;46:386–387
  17. Ravert HT, Bencherif B, Madar I, Frost JJ. PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Des. 2004;10:759–768
  18. Talbot PS, Narendran R, Butelman ER, Huang Y, Ngo K, Slifstein M, et al. [11C]-GR103545, a radiotracer for imaging k-opioid receptors in vivo with PET : synthesis and evaluation in baboons. J Nucl Med. 2005;46:484–494
  19. Ravert HT, Scheffel U, Mathews WB, Musachio JL, Dannals RF. [11C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nucl Med Biol. 2002;29:47–53
  20. Naylor A, Judd DB, Lloyd JE, Scopes DIC, Hayes AG, Birch PJ. A potent new class of k-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. J Med Chem. 1993;36:2075–2083
  21. Soukara S, Maier CA, Predoiu U, Ehret A, Jackisch R, Wünsch B. Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent k-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies. J Med Chem. 2001;44:2814–2826
  22. Butelman ER, Ko MCH, Traynor JR, Vivian JA, Kreek MJ, Woods JH. GR89,696: a potent k-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther. 2001;298:1049–1059
  23. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective k-opioid receptor antagonists. Life Sci. 1987;40:1287–1292
  24. Jones RM, Portoghese PS. 5′-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur J Pharmacol. 2000;396:49–52
  25. Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, et al. Identification of the first trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid k receptor antagonist activity. J Med Chem. 2001;44:2687–2690
  26. Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Peretta CL, Fix SE, et al. Identification of (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a novel potent and selective opioid k receptor antagonist. J Med Chem. 2003;46:3127–3137
  27. Carroll FI, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, et al. Pharmacological properties of JDTic: a novel k-opioid receptor antagonist. Eur J Pharmacol. 2004;501:111–119
  28. Carroll FI, Harris LS, Aceto MD. Effects of JDTic, a selective k-opioid antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. Eur J Pharmacol. 2005;524:89–94
  29. Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology. 2005;183:118–126
  30. Antoni G, Kihlberg T, Långström B. Aspects on the synthesis of 11C-labelled compounds. In:  Welch MJ,  Redvanly CS editor. Handbook of radiopharmaceuticals — Radiochemistry and applications. Chichester, England: Wiley; 2003;p. 141–194Chapter 5
  31. Van der Mey M, Windhorst AD, Klok RP, Herscheid JDM, Kennis LE, Bischoff F, et al. Synthesis and biodistribution of [11C]R107474, a new radiolabeled a2-adrenoceptor antagonist. Bioorg Med Chem. 2006;14:4526–4534and references cited
  32. Crouzel C, Långström B, Pike VW, Coenen HH. Recommendations for a practical production of [11C]-methyl iodide. Appl Radiat Isot. 1987;38:601–603
  33. Jewett DM. A simple synthesis of [11C]-methyl triflate. Appl Radiat Isot. 1992;43:1383–1385
  34. Kitchen I, Slowe SS, Matthes HWD, Kieffer B. Quantitative autoradiographic mapping of µ-, d- and k-opioid receptors in knockout mice lacking the µ-opioid receptor gene. Brain Res. 1997;778:73–88
  35. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66:2221–2231
  36. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376–389
  37. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376–389
  38. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. 1997;
  39. DePaoli AM, Hurley KM, Yasada K, Reisine T, Bell G. Distribution of k-opioid receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study. Mol Cell Neurosci. 1994;5:327–335
  40. Takemori AE, Sultana M, Nagase H, Portoghese PS. Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone. Life Sci. 1992;50:1491–1495

PII: S0969-8051(08)00062-0

doi: 10.1016/j.nucmedbio.2008.02.010

Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 561-569 , July 2008

Article Tools

* Image Usage & Resolution